Susquehanna International Group, LLP Vera Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$34.09 - $46.71 $1.88 Million - $2.58 Million	55,200 Added 138.69%	95,000 $4.2 Million
Q2 2024 Aug 15, 2024	SELL	$33.72 - $48.82 $1.59 Million - $2.3 Million	-47,200 Reduced 54.25%	39,800 $1.44 Million
Q1 2024 May 07, 2024	BUY	$14.91 - $49.14 $1.3 Million - $4.28 Million	87,000 New	87,000 $3.75 Million
Q3 2023 Nov 14, 2023	SELL	$13.71 - $19.64 $564,852 - $809,168	-41,200 Reduced 78.33%	11,400 $156,000
Q2 2023 Aug 11, 2023	BUY	$6.11 - $17.83 $212,017 - $618,700	34,700 Added 193.85%	52,600 $844,000
Q1 2023 May 16, 2023	BUY	$5.41 - $18.3 $96,839 - $327,570	17,900 New	17,900 $138,000

184

55.1M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.31B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.